LOS ANGELES

,

June 23, 2021

/PRNewswire/ —


Glancy Prongay

& Murray LLP

(“GPM”) reminds investors of the upcoming


August 9

, 2021

deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired AcelRx Pharmaceuticals, Inc. (“AcelRx” or the “Company”) (NASDAQ:

ACRX

) securities between


March 17, 2020

and

February 12, 2021


, inclusive (the “Class Period”).

If you suffered a loss on your AcelRx investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at

https://www.glancylaw.com/cases/acelrx-pharmaceuticals-inc/

. You can also contact

Charles H. Linehan

, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at

[email protected]

to learn more about your rights.

AcelRx is a pharmaceutical company that develops therapies for the treatment of acute pain. One of its lead product candidates is DSUVIA, which has been approved by the U.S. Food and Drug Administration (“FDA”) for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings.

On

February 16, 2021

, AcelRx disclosed that it had received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, the FDA concluded that certain of AcelRx’s promotional communications “make false or misleading claims and representations about the risks and efficacy of DSUVIA,” and “[t]hus . . . misbrand Dsuvia within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.”

On this news, AcelRx’s stock price fell

$0.21

per share, or 8.37%, to close at

$2.30

per share on

February 16, 2021

, thereby injuring investors.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (2) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (3) the foregoing conduct subjected the Company to increased regulatory scrutiny and enforcement; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on

LinkedIn

,

Twitter

, or

Facebook

.

If you purchased or otherwise acquired AcelRx securities during the Class Period, you may move the Court no later than


August 9, 2021




to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact

Charles Linehan, Esquire

, of GPM, 1925 Century Park East, Suite 2100,

Los Angeles, California

90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to

[email protected]

, or visit our website at

www.glancylaw.com

.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content:

http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-acelrx-pharmaceuticals-inc-acrx-301318291.html

SOURCE

Glancy Prongay

& Murray LLP